An observational study in Drug Resistant Epilepsy and Ketogenic Dieting, sponsored by Nutricia Nutrition Clinique. Recruiting at 1 site in France. Open to participants aged 5 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Nutricia Nutrition Clinique (part of Danone) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Drug Resistant Epilepsy with a site in France — 16 open to participants now, 17 under way, 1 of them phase 3. Drug Resistant Epilepsy · France.
Among the 35 studies in Drug Resistant Epilepsy with a site in France, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 7 that started in 2024, is one of 11 observational ones, reaches primary completion later than 8 of the 16 other live ones, and was the 25th registered.
258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.
Browse Drug Resistant Epilepsy studies →16 of the 35 studies in Drug Resistant Epilepsy with a site in France are open now. Recruiting first, the newest first:
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 12+
Hospices Civils de Lyon · Sites in France
Ages 18–60 · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 5–25
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–65
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 9+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.
This study: 5 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 8
First in 2005; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 133 is above the median of 86 across 45 observational studies indexed under Drug Resistant Epilepsy.
Median enrollment 82 across the 24 interventional studies, 110 across the 11 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 35 have an industry lead sponsor. The 10 most frequent:
This study is registered under Nutricia Nutrition Clinique, one of the names counted as Danone. Under that name alone:
Nutricia Nutrition Clinique is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Danone has 3 studies filed under Drug Resistant Epilepsy — fewer than ten, so there is no comparison to draw.
6 of the studies in Drug Resistant Epilepsy with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT06334952Assistance Publique Hopitaux De MarseilleEfficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic | 2026-12-18 |
| NCT06138808Duke University5-SENSE Score Validation Study | 2027-01 |
| NCT07898397University Hospital, Strasbourg, FranceLong-Term Epilepsy Outcomes in Children With a History of Perinatal Stroke | 2027-02-28 |
Add all 6 to your calendar (.ics) → With an account.
Among the 35 studies in Drug Resistant Epilepsy with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, prospective, observational, longitudinal study designed to describe the therapeutic value of the KetoCal® range in the maintenance of a ketogenic diet during the management of infants (from 5 months) and children up to 17 years of age (i.e. 18 years minus 1 day) with drug-resistant epilepsy.
This study is being conducted according to standard medical practice. No change in diagnostic or therapeutic management habits is imposed by this study. Quality of life questionnaires are the only additional procedures for this research.
NUTRICIA has developed the KetoCal® range (4:1 and 3:1), a food for special medical purposes (DADFMS), to help healthcare professionals and patients establish and maintain a CR. KetoCal® 4:1 features a 4:1 ratio of fat to (carbohydrate + protein), while containing vitamins, minerals, trace elements and fiber. Similarly, KetoCal® 3:1 has a 3:1 ratio of lipids / (carbohydrates + proteins), while containing vitamins, minerals, trace elements and fiber. The KetoCal® range can be consumed orally, as a drink after dilution in hot water, incorporated as an ingredient in a recipe or administered by enteral feeding tube.
The KEOPS study is designed to gather real-life data on the therapeutic value of using the KetoCal® range in the management of drug-resistant epilepsy in infants (from 5 months) and children up to 18 years of age. Patients will be managed according to standard care practices. Initiation of ketogenic dieting will be at the investigator's discretion during the child's hospitalization.
A total of 133 eligible patients will be recruited in this project. The target population of our project will be infants (from 5 months of age) and children up to 18 years of age treated for drug-resistant epilepsy, who, depending on the physician in charge of the patient, may benefit from the initiation of a KetoCal® 3:1 or 4:1 CR, depending on the child's age.
We exclude from our study protected legal representatives of minors (under guardianship, curatorship, minor parents). In addition, people taking part in this study will not be able to take part in any other interventional or observational research for the duration of the study. A 6-month exclusion period is planned as part of this project.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ancillary study eligibility criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infants (from 5 months) and children up to 17 years of age follow up for drug resistant epilepsy
Other: Ketocal
ketogene diet
Description of compliance
Retention rate which is defined as the proportion of patients who have continued KD for up to 6 months.
Time frame: 6 months
Duration of compliance
Describe the duration of KD compliance.
Time frame: From Month 1 to Month 6
Efficacy of KD
Describe the efficacy of KD. Efficacy is defined as responders to KD with seizure frequency reduced by more than 50%, or no seizure frequency in the case of total response to CR in the last week.
Time frame: From Month 1 to Month 6
KD tolerance.
Describe KD tolerance as a number of AE reported
Time frame: From inclusion to Month 6
QoL evolution
Describe changes in patients' quality of life following initiation of KD at inclusion, and M6; using PedsQL ™ questionnaires
Time frame: From inclusion to Month 6
Influence of KD
Total number of antiepileptic drugs used for each child including their current treatment until the end of the study.
Time frame: From inclusion to Month 6
Ketosis achievement
Evaluate the time it takes to achieve ketosis. Ketosis will be assessed by ketonuria or ketonemia, depending on the habits of each center.
Time frame: From inclusion to Month 6
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Jun 2027, 41 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.